ARTICLE | Clinical News
G4460: Phase I started
October 23, 2006 7:00 AM UTC
GNTA started a dose-escalation, U.S. Phase I trial in patients with hematologic cancers. The compound has Orphan Drug designation in the U.S. to treat chronic myelocytic leukemia (CML). ...